Rakovina therapeutics to present research highlighting small-molecule bifunctional inhibitors of parp1/2 and hdac enzymes at the 36th eortc-nci-aacr symposium in barcelona spain

Vancouver, british columbia, oct. 25, 2024 (globe newswire) -- rakovina therapeutics inc. (tsx-v: rkv) (“rakovina” or the “company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel dna-damage response targeting technologies, is pleased to announce the presentation of its research on novel small-molecule bifunctional inhibitors of parp1/2 and hdac enzymes at the 36th eortc-nci-aarc symposium in barcelona, spain, on october 25, 2024.
NCI Ratings Summary
NCI Quant Ranking